Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients
Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients
复制标题
DOI：
10.2169/internalmedicine.3597-19
复制
发表时间：
2020-01-01
影响因子：
1.2
通讯作者：
Kuro-o, Makoto
中科院分区：
文献类型：
--
作者：
Yamamoto, Shogo;Koyama, Daisuke;Kuro-o, Makoto
目的预防老年性疾病，如骨质疏松症和脑血管病，是老年人长期卧床不起的主要原因。这些疾病的早期可预测的生物标志物在临床上是迫切需要的。成纤维细胞生长因子（FGF）家族的三个成员-FGF 19，FGF 21和FGF 23-被指定为内分泌FGF，并在各种代谢过程中发挥关键作用。方法采用单中心横断面研究方法，对73例60岁以上老年患者进行血清FGF水平检测，并分析其与各种临床指标的相关性。结果在多变量线性回归分析中，FGF 19与ALT、心血管疾病史、以及含有活性维生素D-3的药物。FGF 21与估计的肾小球滤过率（eGFR）、甘油三酯水平和高血压相关。FGF 23与eGFR和血清1，25-二羟基维生素D-3和TRACP 5 b水平相关。此外，受试者操作特征分析显示，FGF 21和FGF 23的测量对于检测慢性肾脏疾病（CKD）及其并发症是有用的。结论FGF 21和FGF 23的检测可用于评价CKD及其并发症。使用血清内分泌FGF作为年龄相关疾病的生物标志物可能有助于防止老年患者进入卧床不起状态。
Objective To prolong the health expectancy, it is important to prevent age-related diseases, such as osteoporosis and cerebrovascular disease, which are major causes of a bedridden state. Early predictable biomarkers for these diseases are urgently required in the clinical setting. Three members of the fibroblast growth factor (FGF) family - FGF19, FGF21, and FGF23 - are designated as endocrine FGFs and play crucial roles in various metabolic processes. We tried to clarify the clinical utility of endocrine FGFs as biomarkers for age-related diseases in elderly patients.Methods We examined the serum endocrine FGF levels and analyzed their association with various clinical parameters in 73 outpatients >60 years old as a single-center cross-sectional study.Results In a multivariable linear regression analysis, FGF19 was associated with ALT, a history of cardiovascular disease, and medication with active vitamin D-3. FGF21 was associated with the estimated glomerular filtration rate (eGFR), triglyceride level, and hypertension. FGF23 was associated with the eGFR and the serum levels of 1,25-dihydroxy vitamin D-3 and TRACP5b. In addition, a receiver operating characteristics analysis revealed that the measurement of FGF21 and FGF23 was useful for detecting chronic kidney disease (CKD) and its complications. including cardiovascular disease and metabolic bone disorder.Conclusion The measurement of FGF21 and FGF23 may be useful for evaluating CKD and its complications. Using serum endocrine FGFs as biomarkers for age-related conditions may help prevent elderly patients from entering a bedridden state.